keyword
MENU ▼
Read by QxMD icon Read
search

Cancer Related Fatigue

keyword
https://www.readbyqxmd.com/read/28528393/chronic-and-episodic-stress-predict-physical-symptom-bother-following-breast-cancer-diagnosis
#1
Lauren N Harris, Margaret R Bauer, Joshua F Wiley, Constance Hammen, Jennifer L Krull, Catherine M Crespi, Karen L Weihs, Annette L Stanton
Breast cancer patients often experience adverse physical side effects of medical treatments. According to the biobehavioral model of cancer stress and disease, life stress during diagnosis and treatment may negatively influence the trajectory of women's physical health-related adjustment to breast cancer. This longitudinal study examined chronic and episodic stress as predictors of bothersome physical symptoms during the year after breast cancer diagnosis. Women diagnosed with breast cancer in the previous 4 months (N = 460) completed a life stress interview for contextual assessment of chronic and episodic stress severity at study entry and 9 months later...
May 20, 2017: Journal of Behavioral Medicine
https://www.readbyqxmd.com/read/28508278/physiotherapy-programme-reduces-fatigue-in-patients-with-advanced-cancer-receiving-palliative-care-randomized-controlled-trial
#2
Anna Pyszora, Jacek Budzyński, Agnieszka Wójcik, Anna Prokop, Małgorzata Krajnik
PURPOSE: Cancer-related fatigue (CRF) is a common and relevant symptom in patients with advanced cancer that significantly decreases their quality of life. The aim of this study was to evaluate the effect of a physiotherapy programme on CRF and other symptoms in patients diagnosed with advanced cancer. METHODS: The study was designed as a randomized controlled trial. Sixty patients diagnosed with advanced cancer receiving palliative care were randomized into two groups: the treatment group (n = 30) and the control group (n = 30)...
May 16, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28503042/assessment-of-cancer-related-fatigue-among-cancer-patients-receiving-various-therapies-a-cross-sectional-observational-study
#3
Raja Paramjeet Singh Banipal, Harminder Singh, Baltej Singh
OBJECTIVE: The objective of this cross-sectional, noninterventional 3-month observational study was to analyze the prevalence of the cancer-related fatigue (CRF) in cancer patient populations with correlation of CRF with different treatment modalities. MATERIALS AND METHODS: A descriptive study was carried out jointly by the pharmacology and oncology departments of a tertiary care center in the Malwa region of Punjab. The data collection was performed by administering the validated Brief Fatigue Inventory (BFI) after obtaining the informed consent...
April 2017: Indian Journal of Palliative Care
https://www.readbyqxmd.com/read/28501804/exercise-and-other-non-pharmaceutical-interventions-for-cancer-related-fatigue-in-patients-during-or-after-cancer-treatment-a-systematic-review-incorporating-an-indirect-comparisons-meta-analysis
#4
REVIEW
Roger Hilfiker, Andre Meichtry, Manuela Eicher, Balfe Lina Nilsson, Ruud H Knols, Martin L Verra, Jan Taeymans
AIM: To assess the relative effects of different types of exercise and other non-pharmaceutical interventions on cancer-related fatigue (CRF) in patients during and after cancer treatment. DESIGN: Systematic review and indirect-comparisons meta-analysis. DATA SOURCES: Articles were searched in PubMed, Cochrane CENTRAL and published meta-analyses. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised studies published up to January 2017 evaluating different types of exercise or other non-pharmaceutical interventions to reduce CRF in any cancer type during or after treatment...
May 13, 2017: British Journal of Sports Medicine
https://www.readbyqxmd.com/read/28500901/the-course-of-cancer-related-fatigue-up-to-ten-years-in-early-breast-cancer-patients-what-impact-in-clinical-practice
#5
Alessandra Fabi, Chiara Falcicchio, Diana Giannarelli, Gabriella Maggi, Francesco Cognetti, Patrizia Pugliese
Little is known about the cancer related fatigue (CRF) along cancer course and risk factors that could predict CRF development and persistence in breast cancer (BC) survivors. This prospective study detected incidence, timing of onset, duration of CRF, impact on QoL and psychological distress. Seventy-eight early BC patients, undergoing chemotherapy (CT) followed or not by hormonal therapy were assessed for QoL and psychological distress by EORTC QLQC30 and HADs questionnaires. Fatigue was investigated with mix methods, structured interview and psychometric measures...
May 10, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28497756/s-1-versus-placebo-in-patients-with-sorafenib-refractory-advanced-hepatocellular-carcinoma-s-cube-a-randomised-double-blind-multicentre-phase-3-trial
#6
Masatoshi Kudo, Michihisa Moriguchi, Kazushi Numata, Hisashi Hidaka, Hironori Tanaka, Masafumi Ikeda, Seiji Kawazoe, Shinichi Ohkawa, Yozo Sato, Shuichi Kaneko, Junji Furuse, Madoka Takeuchi, Xuemin Fang, Yoshito Date, Masahiro Takeuchi, Takuji Okusaka
BACKGROUND: Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited. We assessed the efficacy and safety of S-1, a chemotherapeutic agent based on fluorouracil, in patients with sorafenib-refractory advanced hepatocellular carcinoma. METHODS: We did a randomised, double-blind, placebo-controlled, phase 3 study done at 57 sites in Japan...
June 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28496354/factors-associated-with-prescription-opioid-misuse-in-a-cross-sectional-cohort-of-patients-with-chronic-non-cancer-pain
#7
Jennifer M Hah, John A Sturgeon, Jennifer Zocca, Yasamin Sharifzadeh, Sean C Mackey
OBJECTIVE: To examine demographic features, psychosocial characteristics, pain-specific behavioral factors, substance abuse history, sleep, and indicators of overall physical function as predictors of opioid misuse in patients presenting for new patient evaluation at a tertiary pain clinic. METHODS: Overall, 625 patients with chronic non-cancer pain prospectively completed the Collaborative Health Outcomes Information Registry, assessing pain catastrophizing, National Institutes of Health Patient-Reported Outcomes Measurement Information System standardized measures (pain intensity, pain behavior, pain interference, physical function, sleep disturbance, sleep-related impairment, anger, depression, anxiety, and fatigue), and substance use history...
2017: Journal of Pain Research
https://www.readbyqxmd.com/read/28489510/safety-and-antitumor-activity-of-pembrolizumab-in-advanced-programmed-death-ligand-1-positive-endometrial-cancer-results-from-the-keynote-028-study
#8
Patrick A Ott, Yung-Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J Pishvaian, Hope S Rugo, Igor Puzanov, Janice M Mehnert, Kyaw L Aung, Juanita Lopez, Marion Carrigan, Sanatan Saraf, Mei Chen, Jean-Charles Soria
Purpose The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti-programmed death 1 monoclonal antibody, in patients with programmed death ligand 1 (PD-L1) -positive advanced solid tumors. The results from the advanced endometrial cancer cohort are reported. Patients and Methods Female patients with locally advanced or metastatic PD-L1-positive endometrial cancer who had experienced progression after standard therapy were eligible. Patients received pembrolizumab 10 mg/kg every 2 weeks for up to 24 months or until progression or unacceptable toxicity...
May 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28489508/tai-chi-chih-compared-with-cognitive-behavioral-therapy-for-the-treatment-of-insomnia-in-survivors-of-breast-cancer-a-randomized-partially-blinded-noninferiority-trial
#9
Michael R Irwin, Richard Olmstead, Carmen Carrillo, Nina Sadeghi, Perry Nicassio, Patricia A Ganz, Julienne E Bower
Purpose Cognitive behavioral therapy for insomnia (CBT-I) and Tai Chi Chih (TCC), a movement meditation, improve insomnia symptoms. Here, we evaluated whether TCC is noninferior to CBT-I for the treatment of insomnia in survivors of breast cancer. Patients and Methods This was a randomized, partially blinded, noninferiority trial that involved survivors of breast cancer with insomnia who were recruited from the Los Angeles community from April 2008 to July 2012. After a 2-month phase-in period with repeated baseline assessment, participants were randomly assigned to 3 months of CBT-I or TCC and evaluated at months 2, 3 (post-treatment), 6, and 15 (follow-up)...
May 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28484088/radium-223-for-primary-bone-metastases-in-patients-with-hormone-sensitive-prostate-cancer-after-radical-prostatectomy
#10
Vera Wenter, Annika Herlemann, Wolfgang P Fendler, Harun Ilhan, Natalia Tirichter, Peter Bartenstein, Christian G Stief, Christian la Fougère, Nathalie L Albert, Axel Rominger, Christian Gratzke
Radium-223 dichloride (Ra-223) is the first bone-targeting agent showing improvement in overall survival in patients with castration-resistant prostate cancer (CRPC) and bone metastases. We aimed to assess feasibility of Ra-223 treatment in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Ten patients with primary bone metastases received Ra-223 following radical prostatectomy (RP). Changes in alkaline phosphatase (ALP) and prostate-specific antigen (PSA) were recorded, while pain intensity was evaluated using the self-reporting Brief Pain Inventory (BPI) questionnaire...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28481185/eribulin-across-multiple-lines-of-chemotherapy-a-retrospective-study-on-quality-of-life-and-efficacy-in-metastatic-breast-cancer-patients
#11
Erica Quaquarini, Federico Sottotetti, Daniela D'Ambrosio, Alberto Malovini, Stefania Morganti, Arianna Marinello, Lorenzo Pavesi, Mara Frascaroli
This study evaluates efficacy, tolerability and health-related quality of life of eribulin in patients with metastatic breast cancer. Predictive and/or prognostic factors of outcome were also analyzed. Among 44 women receiving eribulin mesylate, one patient had a complete response, 22.7% a partial response and 25% a stable disease. Median overall survival and median progression-free survival were 11.8 and 4.5 months, respectively. Treatment was well tolerated; the most frequent adverse events were neutropenia (52%), leukopenia (50%), fatigue (38%) and alopecia (40%)...
April 2017: Future Oncology
https://www.readbyqxmd.com/read/28479368/safety-analyses-of-pemetrexed-cisplatin-and-pemetrexed-maintenance-therapies-in-patients-with-advanced-non-squamous-nsclc-retrospective-analyses-from-2-phase-iii-studies
#12
Corey J Langer, Luis G Paz-Ares, Antoinette J Wozniak, Cesare Gridelli, Filippo de Marinis, Jean-Louis Pujol, Belen San Antonio, Jian Chen, Jingyi Liu, Ana B Oton, Carla Visseren-Grul, Giorgio V Scagliotti
BACKGROUND: In a phase III study, maintenance pemetrexed showed superior survival over placebo (PARAMOUNT) for patients with advanced non-squamous non-small cell lung cancer (NSCLC) who completed 4 cycles of pemetrexed plus cisplatin (PC) induction therapy, with low incidence of treatment-emergent adverse events (TEAEs) generally associated with pemetrexed. Prior analyses did not account for toxicities carried over from induction; thus, the current analysis was developed to understand toxicities that may be attributed to pemetrexed maintenance versus PC induction, and how treatment duration affects toxicity...
April 12, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28478862/symptoms-and-health-related-quality-of-life-in-patients-with-advanced-cancer-a-population-based-study-in-greenland
#13
Mikaela Augustussen, Per Sjøgren, Helle Timm, Lise Hounsgaard, Michael Lynge Pedersen
PURPOSE: The aims were to describe symptoms and health-related quality of life (HRQoL) in Greenlandic patients with advanced cancer and to assess the applicability and internal consistency of the Greenlandic version of the EORTC-QLQ-C30 core version 3.0. METHODS: A Greenlandic version of the EORTC QLQ-C30 v.3.0 was developed. The translation process included independent forward translation, reconciliation and independent back translation by native Greenlandic-speaking translators who were fluent in English...
June 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/28478855/the-importance-of-self-care-for-fatigue-amongst-patients-undergoing-chemotherapy-for-primary-cancer
#14
Patricia O' Regan, Josephine Hegarty
PURPOSE: To measure Cancer Related Fatigue (CRF), and explore fatigue self-care strategies used to ameliorate CRF amongst patients undergoing chemotherapy for primary cancer. METHODS: A consecutive sample of patients (n = 362) undergoing chemotherapy with a primary diagnosis of breast, colorectal, Hodgkin's and non-Hodgkin's lymphoma cancers were recruited. A mixed methods design was utilised. The study questionnaires included: the Piper Fatigue Scale-Revised and a researcher developed fatigue Self-Care Survey...
June 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/28476513/animal-models-of-cachexia-and-sarcopenia-in-chronic-illness-cardiac-function-body-composition-changes-and-therapeutic-results
#15
REVIEW
Junichi Ishida, Masakazu Saitoh, Wolfram Doehner, Stephan von Haehling, Markus Anker, Stefan D Anker, Jochen Springer
Cachexia is defined as a complex metabolic syndrome associated with underlying illness that is characterized by the loss of body weight consisting of muscle and fat mass wasting. Sarcopenia is defined as the ageing related loss of muscle mass in health and disease that may not have an effect on body weight. As millions of patients are in cachectic or sarcopenic states, both conditions contribute to high numbers to death worldwide. A number of treatments have been proposed for cachexia and sarcopenia, but these are either in the preclinical stage or in clinical trials and hence not available to the general population...
April 2, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28475614/serum-chemerin-levels-are-independently-associated-with-quality-of-life-in-colorectal-cancer-survivors-a-pilot-study
#16
Jee-Yon Lee, Mi-Kyung Lee, Nam-Kyu Kim, Sang-Hui Chu, Duk-Chul Lee, Hye-Sun Lee, Ji-Won Lee, Justin Y Jeon
BACKGROUND: Colorectal cancer (CRC) survivors are known to experience various symptoms that significantly affect their quality of life (QOL); therefore, it is important to identify clinical markers related with CRC survivor QOL. Here we investigated the relationship between serum chemerin levels, a newly identified proinflammatory adipokine, and QOL in CRC survivors. METHODS: A data of total of 110 CRC survivors were analysed in the study. Serum chemerin levels were measured with an enzyme immunoassay analyser...
2017: PloS One
https://www.readbyqxmd.com/read/28474541/the-effect-of-thyroid-related-symptoms-on-long-term-quality-of-life-in-patients-with-differentiated-thyroid-carcinoma-a-population-based-study-in-sweden
#17
Christel Hedman, Therese Djärv, Peter Strang, Catharina Ihre Lundgren
BACKGROUND: Differentiated thyroid cancer (DTC) has a good prognosis but a remaining risk of recurrence, and life-long follow-up as well as medication with levothyroxine may be necessary. The aim of this study was to clarify how thyroid-related symptoms affect health-related quality of life (HRQoL) 14-17 years after diagnosis, in Swedish DTC patients. METHODS: From the all-encompassing population-based Swedish Cancer Registry, 353 patients diagnosed with DTC during 1995-1998 were identified and invited to answer a study-specific questionnaire and the HRQoL questionnaire SF-36, 14-17 years after their diagnosis...
May 5, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28470368/breast-cancer-survivors-preferences-for-technology-supported-exercise-interventions
#18
Siobhan M Phillips, David E Conroy, Sarah Kozey Keadle, Christine A Pellegrini, Gillian R Lloyd, Frank J Penedo, Bonnie Spring
PURPOSE: The purpose of this study was to explore breast cancer survivors' interest in and preferences for technology-supported exercise interventions. METHODS: Post-treatment survivors [n = 279; M age = 60.7 (SD = 9.7)] completed a battery of online questionnaires in August 2015. Descriptive statistics were calculated for all data. Logistic regression analyses were conducted to examine relationships between survivors' interest in a technology-supported exercise interventions and demographic, disease, and behavioral factors...
May 3, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28468797/selective-inhibition-of-nuclear-export-with-selinexor-in-patients-with-non-hodgkin-s-lymphoma
#19
John Kuruvilla, Michael Savona, Rachid Baz, Morten Mau-Sorensen, Nashat Gabrail, Ramiro Garzon, Richard Stone, Michael Wang, Lynn Savoie, Peter Martin, Ian Flinn, Meagan Jacoby, T J Unger, Jean R Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham, Martin Gutierrez
Patients with relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D). Seventy-nine patients with various NHL histologies, including diffuse large B cell lymphoma (DLBCL), Richter's transformation, mantle cell lymphoma (MCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) were enrolled...
May 3, 2017: Blood
https://www.readbyqxmd.com/read/28468766/regorafenib-induced-hypothyroidism-and-cancer-related-fatigue-is-there-a-potential-link
#20
Fabiana Pani, Matteo Massidda, Valeria Pusceddu, Marco Puzzoni, Elena Massa, Clelia Madeddu, Mario Scartozzi, Stefano Mariotti
OBJECTIVE: Thyroid dysfunction has been reported during Regorafenib (Reg) administration, but no detailed study is presently available. DESIGN: Prospective, observational cohort study. Patients with documented metastatic colorectal cancer and progression of disease during or within 3 months after the last standard therapy, with no evidence and history of previous thyroid disease were enrolled. METHODS: Twenty-five consecutive patients were evaluated before and 8-50 weeks after initiating Reg therapy by monthly clinical, ultrasound and laboratory (thyrotropin [TSH], free thyroxine [fT4], antithyroglobulin [TgAb] and antithyroid peroxidase [TPOAb]) evaluation...
May 3, 2017: European Journal of Endocrinology
keyword
keyword
39569
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"